Latest Oxaliplatin Stories
WOODCLIFF LAKE, N.J., April 5 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc.
NEW YORK, April 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that the U.S.
LAKE FOREST, Ill., April 1 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced it has reached a legal settlement with Sanofi-Aventis to resolve patent litigation concerning Hospira's U.S.
WALTHAM, Mass., March 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that improves disease-free survival over FOLFOX4* at three years for the treatment of stage III colon cancer would earn a 55 percent patient share in the United States, according to surveyed U.S.
WALTHAM, Mass., March 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy that would improve median overall survival over IFL (bolus 5-fluorouracil, generics/leucovorin, generics/irinotecan*) plus bevacizumab (Roche/Genentech/Chugai's Avastin), would earn a 60 percent patient share in stage IV colorectal cancer, according to surveyed U.S.
DETROIT, March 11 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE: CPD) has launched oxaliplatin injections.
Phase 3 X-PECT Trial (Xeloda(R) + Perifosine Evaluation in Colorectal cancer Treatment) to be led by Dr. Johanna Bendell, Director, GI Oncology Research, Sarah Cannon Research Institute QUEBEC CITY, Feb. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, Feb. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S.
NEW YORK, Jan. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc.